|Trade names||Zavedos, Idamycin, others|
|Other names||Idarubicin hydrochloride, 4-demethoxydaunorubicin, 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione|
|Main uses||Acute myeloid leukemia (AML), breast cancer|
|Side effects||Nausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, headache|
|Elimination half-life||22 hours|
|Chemical and physical data|
|Molar mass||497.500 g·mol−1|
|3D model (JSmol)|
Idarubicin, sold under the brand name Zavedos and Idamycin, is a medication used to treat acute myeloid leukemia (AML) and breast cancer. It is often used with cytarabine. It is given by injection into a vein or taken by mouth.
Common side effects include nausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, and headache. Other side effects may include heart failure, arrhythmias, bone marrow suppression, high uric acid, liver problems, kidney problems. Use in pregnancy may harm the baby. It is an anthracycline and acts similar to daunorubicin.
Idarubicin was approved for medical use in the United States in 1990. In the United Kingdom 10 mg for injection costs the NHS about £175 as of 2021. In the United States this amount costs about 70 USD.
- "Doxorubicin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 16 May 2021. Retrieved 25 November 2021.
- "IDArubicin Monograph for Professionals". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 948. ISBN 978-0857114105.
- "Idarubicin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.
- "Idarubicin Side Effects: Common, Severe, Long Term". Drugs.com. Archived from the original on 2019-06-21. Retrieved 2019-06-21.